Evidence map›Paper›PMID 26962464›Full record

ReviewBone research2016

Current research on pharmacologic and regenerative therapies for osteoarthritis.

Wei Zhang, Hongwei Ouyang, Crispin R Dass, Jiake Xu

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Bone research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05660824 (Effectiveness of Stromal Vascular Fraction), which is not on this map. Cited by 240 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
240citing papers in PubMed, 3 pooled it
40.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05660824 phase4not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Effectiveness of Stromal Vascular Fraction (SVF) and Platelet -Rich Plasma (PRP) in Patients With Knee Osteoarthritis: Study Protocol for a Phase III, Prospective, Randomized, Controlled Multi-center Study : (SPOST Study)

TypeinterventionalSponsorAdrien SchwitzguebelRan2025 to 2027Enrolled108ConditionsOsteoarthritisArmsStromal Vascular Fraction infiltration, Plattelet Rich Plasma infiltration
3 · Its place in the literature

Who cites it

240 citing papers in PubMed, 3 syntheses or guidelines pooled it, 487 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

180 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Wei ZhangCenter for Stem Cell and Tissue Engineering, School of Medicine, Zhejiang University, Hangzhou 310058, China; School of Pathology and Laboratory Medicine, The University of Western Australia, Perth WA 6009, Australia.
Hongwei OuyangCenter for Stem Cell and Tissue Engineering, School of Medicine, Zhejiang University , Hangzhou 310058, China.
Crispin R DassSchool of Pharmacy, Building 306, Curtin University , Bentley, Perth WA 6102, Australia.
Jiake XuSchool of Pathology and Laboratory Medicine, The University of Western Australia , Perth WA 6009, Australia.
Zhejiang University · CNCurtin University · AUUniversity of Western Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoarthritis (OA) is a degenerative joint disorder commonly encountered in clinical practice, and is the leading cause of disability in elderly people. Due to the poor self-healing capacity of articular cartilage and lack of specific diagnostic biomarkers, OA is a challenging disease with limited treatment options. Traditional pharmacologic therapies such as acetaminophen, non-steroidal anti-inflammatory drugs, and opioids are effective in relieving pain but are incapable of reversing cartilage damage and are frequently associated with adverse events. Current research focuses on the development of new OA drugs (such as sprifermin/recombinant human fibroblast growth factor-18, tanezumab/monoclonal antibody against β-nerve growth factor), which aims for more effectiveness and less incidence of adverse effects than the traditional ones. Furthermore, regenerative therapies (such as autologous chondrocyte implantation (ACI), new generation of matrix-induced ACI, cell-free scaffolds, induced pluripotent stem cells (iPS cells or iPSCs), and endogenous cell homing) are also emerging as promising alternatives as they have potential to enhance cartilage repair, and ultimately restore healthy tissue. However, despite currently available therapies and research advances, there remain unmet medical needs in the treatment of OA. This review highlights current research progress on pharmacologic and regenerative therapies for OA including key advances and potential limitations.

Identifiers

PMID26962464
PMCPMC4772471
OpenAlexW2317124801

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.